Travere Therapeutics to Present at SSIEM Symposium
Travere Therapeutics, Inc. (NASDAQ: TVTX) has announced its participation in an upcoming symposium where the company will present innovative research focused on classical homocystinuria (HCU). This event is set to take place in Porto, Portugal, from September 3 to 6, and will include two important poster presentations regarding their investigational enzyme replacement therapy, pegtibatinase.
Overview of Poster Presentations
During the Society for the Study of Inborn Errors of Metabolism (SSIEM) symposium, Travere Therapeutics will reveal the trial designs for the pivotal Phase 3 HARMONY Study, as well as the long-term ENSEMBLE extension study centered on pegtibatinase. This cutting-edge therapy aims to tackle the underlying causes of classical HCU by potentially restoring the activity of the deficient cystathionine beta synthase (CBS) enzyme.
Details on the Poster Presentations
The first presentation will showcase the designs of the HARMONY and ENSEMBLE Phase 3 studies for pegtibatinase, which is scheduled for September 4, 2024. This poster, categorized under clinical studies and patient-reported outcomes, will explore the study methods and strategies for engaging patients.
The second presentation will concentrate on the COMPOSE Phase 1/2 study, which specifically assesses the safety of pegtibatinase in children aged 5 to under 12 years with classical HCU. This electronic poster will also highlight significant findings related to clinical outcomes and safety profiles.
Understanding Classical Homocystinuria
Classical homocystinuria is a rare genetic metabolic disorder resulting from a deficiency in the CBS enzyme. This enzyme is crucial for managing the amino acids methionine and cysteine, and its deficiency can lead to dangerously high levels of homocysteine in the body. This condition poses serious health risks, including strokes and various complications that can affect vision, bones, and cognitive development. Current treatment options mainly involve dietary restrictions and supplementation with vitamin B6 and betaine, which do not sufficiently address the underlying enzymatic deficiency.
The Role of Pegtibatinase
Pegtibatinase marks a significant advancement as an investigational PEGylated, recombinant enzyme replacement therapy. Early studies suggest its potential effectiveness in lowering total homocysteine levels, which could lead to improved clinical outcomes for patients suffering from classical HCU. Recently, the company launched the pivotal Phase 3 HARMONY Study, aimed at thoroughly evaluating the efficacy and safety of pegtibatinase.
Recent Clinical Trials and Findings
Promising preliminary data from the Phase 1/2 COMPOSE Study indicated a remarkable 67.1% mean relative reduction in total homocysteine levels among patients receiving the highest dose of pegtibatinase after 12 weeks. These results underscore the potential of pegtibatinase to serve as a transformative treatment option for individuals with classical HCU. The FDA has acknowledged the therapy's potential by granting it Breakthrough Therapy designation, Rare Pediatric Disease designation, and Fast Track designation, highlighting the urgency and importance of this treatment in the healthcare landscape.
About Travere Therapeutics
Travere Therapeutics is committed to enhancing the lives of patients with rare diseases. With a focus on innovation and patient-centered research, the company collaborates closely with healthcare professionals and patients to develop therapies targeting rare metabolic disorders. By prioritizing safety and efficacy, Travere Therapeutics strives to provide hope and practical solutions for individuals and families facing the challenges of rare diseases.
Contact Information
For inquiries, Travere Therapeutics can be contacted at the following:
Media Contact:
Phone: 888-969-7879
Email: mediarelations@travere.com
Investor Contact:
Phone: 888-969-7879
Email: IR@travere.com
Frequently Asked Questions
What is classical homocystinuria?
Classical homocystinuria is a rare genetic disorder caused by a deficiency in the CBS enzyme, which leads to elevated levels of homocysteine in the body.
What is the role of pegtibatinase?
Pegtibatinase is an investigational therapy aimed at replacing the deficient CBS enzyme, with the goal of reducing homocysteine levels in patients diagnosed with classical HCU.
When will the findings of the trials be available?
The findings from the presentations at the SSIEM symposium will be shared during the event, with additional details likely to be published in scientific journals afterward.
What approvals has pegtibatinase received?
Pegtibatinase has received Breakthrough Therapy designation, Rare Pediatric Disease designation, and Fast Track designation from the FDA.
How can I learn more about Travere Therapeutics?
For more information about the company and its therapies, visit travere.com.
